AMERITRADE
DATEK
Discover Brokerage
DLJDirect
E-Trade
Schwab




To receive immediate notification of research updates, enter your e-mail address here (ex: name@domain.com):


  CTIC
CTIC is an emerging pharmaceutical company focusing on the discovery, development, and commercialization of drugs useful in treating cancer and the serious side effects of various cancer treatments. The Company is building a deep, vertically integrated pipeline of cancer products targeting major unmet treatment needs, each with independent technology. This strategy enables use of multiple CTIC products by the same clinician and patient, and protects against the failure or ineffectiveness of any one particular technology. CTIC's lead product, Lisofylline ("LSF"), is in trials for two different indications: treating the side effects of high-dose chemotherapy and radiation, and for treatment of patients with acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). CTIC has partnered with Johnson & Johnson ("JNJ") for the development of Lisofylline; CTIC is actively seeking additional corporate partners for other drug candidates. We are initiating coverage of CTIC with a BUY rating, and recommend purchase of CTIC by investors tolerant of the risks associated with small-cap equity investments.

SMALLCAPS RESEARCH

Wall Street Interview with CTIC President, Dr. Bianco (RealVideo format) (07/01/99)

Commentary on CTIC following news that it had halted a Phase II/III trial (06/01/99)

Full-Length Initial Opinion (05/12/99)


Financial Model (05/12/99)
Initial Opinion (04/22/99)